Dyne Therapeutics Stock Rises After Positive DM1 Trial Results
Shares of Dyne Therapeutics (NASDAQ: DYN) moved higher in after-hours trading after the biotechnology company reported additional one-year clinical data from its Phase 1/2 ACHIEVE trial of z-basivarsen (DYNE-101) in patients with myotonic dystrophy type 1 (DM1).
The company reported improvements across several measures of physical function and muscle strength after 12 months. Dyne's shares gained about 2.1% in after-hours trading on September 29, 2026, following the data release, according to Investing.com.
The results are important because z-basivarsen is one of Dyne's two lead clinical programs and is already moving into a global Phase 3 study. However, the latest data come from a relatively small pooled group, so investors still have to wait for larger registrational data expected in 2027.
What Dyne Reported From the DM1 Trial
The latest results came from the multiple ascending dose portion of the ACHIEVE trial. Dyne analyzed a pooled group of 25–26 participants who had received different dose levels of z-basivarsen. The company also compared the results with a propensity-matched natural-history cohort of 41–46 participants from the END-DM1 study.
One of the key measurements was video hand opening time (vHOT). The test measures how quickly a patient can open their hand, which can be affected by the muscle stiffness and weakness associated with DM1.
At six months, the pooled z-basivarsen group recorded a mean 3.2-second decrease in vHOT from a baseline of 8.2 seconds. The placebo group recorded a 0.4-second increase, producing a 3.6-second relative difference between the groups.
The company said the improvement continued to support vHOT as an early indicator of potential clinical benefit.
Improvements Were Also Seen in Other Functional Measures
The significance of the latest release is that the company did not rely on a single measurement.
At 12 months, participants showed a 1.2-second improvement from baseline on the five-times-sit-to-stand test and a 0.3-second improvement on the 10-meter walk/run test. Muscle strength also improved by 4.8% on both the quantitative muscle-testing total score and hand-grip score, according to the reported results.
These measures are relevant because DM1 can affect several aspects of physical function. Evidence of improvement across multiple measures can provide additional context around whether a treatment is producing meaningful functional changes.
Still, these findings should not be confused with definitive Phase 3 evidence. The current analysis involves a relatively small number of participants and is part of an ongoing development program.
Why the Results Matter for Dyne Therapeutics
Dyne is developing z-basivarsen as a potential treatment for myotonic dystrophy type 1, a genetic neuromuscular disorder.
The company's approach uses its FORCE platform, which is designed to deliver therapeutic molecules into skeletal and cardiac muscle. Z-basivarsen is intended to address the underlying RNA-related mechanism associated with DM1 rather than simply treating individual symptoms.
Dyne completed enrollment of 71 participants in the registrational expansion cohort of ACHIEVE in June 2026. The company expects topline results from that cohort in the first quarter of 2027.
Those results are particularly important because Dyne intends to use them to support a potential U.S. accelerated-approval submission in the third quarter of 2027.
Phase 3 HARMONIA Trial Is Already Underway
The DM1 program has also progressed beyond the Phase 1/2 setting.
Dyne began dosing patients in the global Phase 3 HARMONIA trial in July 2026. The company is evaluating z-basivarsen in a larger confirmatory study as it advances toward potential regulatory approval.
This creates two important stages for investors to monitor: the ACHIEVE registrational expansion results expected in early 2027 and the longer-term Phase 3 HARMONIA program.
The success of the program will ultimately depend on whether the observed improvements can be reproduced in larger patient populations and whether regulators consider the evidence sufficient for approval.
Dyne Has More Than One Potential Catalyst
The DM1 program is only part of Dyne's investment story.
The company is also developing z-rostudirsen for Duchenne muscular dystrophy (DMD). In July 2026, the FDA accepted Dyne's Biologics License Application for z-rostudirsen and granted Priority Review. The FDA's PDUFA target action date is January 21, 2027.
That means Dyne could face a major regulatory catalyst around the same period as investors await further DM1 data.
The company has also received FDA clearance to begin a Phase 1 study of DYNE-302 for facioscapulohumeral muscular dystrophy (FSHD), expanding its pipeline beyond DMD and DM1.
For investors, this diversification can be important because the company's valuation is influenced by several development programs rather than a single experimental medicine.
Financial Position and Development Risk
Clinical-stage biotechnology companies can experience significant volatility because their valuations often depend heavily on clinical and regulatory milestones.
Dyne reported an expected cash runway into the second quarter of 2028 in its second-quarter 2026 update. The company also amended its senior secured term-loan facility with Hercules Capital, increasing the available debt facility to up to $400 million.
That provides additional financial flexibility as the company funds multiple clinical programs.
However, having capital available does not remove the underlying clinical risk. Experimental treatments can fail to meet endpoints, produce unexpected safety findings or encounter regulatory delays even after encouraging earlier-stage results.
What Investors Should Watch Next
The most important near-term developments for DYN are likely to come from both the DM1 and DMD programs.
For z-basivarsen, investors should watch the ACHIEVE registrational expansion cohort, with topline data expected in Q1 2027. The key issue will be whether the larger cohort confirms the functional improvements observed in the earlier data.
Investors should also track the Phase 3 HARMONIA trial, particularly its enrollment and future efficacy and safety updates.
For z-rostudirsen, the FDA's January 21, 2027 PDUFA date represents another major event for Dyne. The outcome could materially affect the company's development and commercial strategy.
Beyond headline efficacy numbers, investors should pay attention to treatment durability, safety, regulatory feedback, cash usage and the company's ability to advance multiple programs without excessive financing requirements.
Key Risks for DYN Stock
The latest DM1 results are encouraging for the development program, but they do not eliminate the risks associated with investing in a clinical-stage biotech.
The most immediate risk is clinical uncertainty. Results from a small pooled population may not accurately predict outcomes in larger controlled studies.
There is also regulatory risk. Accelerated approval, if pursued, would depend on regulators accepting the company's evidence and development strategy.
Finally, competition in rare neuromuscular diseases is increasing, with multiple biotechnology companies developing RNA-based and genetic medicines. Commercial success would therefore depend not only on approval but also on clinical differentiation, pricing, physician adoption and reimbursement.
Conclusion
Dyne Therapeutics stock moved higher after the company released additional one-year data from its ACHIEVE trial, with z-basivarsen showing improvements across several measures of physical function and muscle strength in patients with DM1.
The results strengthen the clinical narrative around z-basivarsen, but the decisive evidence is still ahead. The Q1 2027 ACHIEVE topline data, progress in the Phase 3 HARMONIA trial, and the FDA's January 2027 decision on z-rostudirsen are key events for investors to monitor.
For DYN shareholders and prospective investors, the central question is whether the early functional improvements can translate into robust, reproducible results in larger trials and ultimately support regulatory approval.
Follow the blog for more biotech, healthcare, stock-market and business updates.
This article is for informational and educational purposes only and should not be considered investment advice.